The text starts here.

News Release

June 3, 1997

Eisai Announces Ground Breaking For Pharmaceutical Production Facility in Suzhou, China

Tokyo (June 3, 1997) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced that Eisai Suzhou Pharmaceutical Co. Ltd. (President: Yusaku Kobayashi), an Eisai affiliate, held a ground-breaking on June 3 in Suzhou, China for a pharmaceutical production facility.

The facility will initially produce NEUQUINON, a metabolic cardiotonic drug, and METHYCOBAL, a peripheral neurophathies remedy and other products which will be submitted for manufacturing approval in China.

At present in China, Eisai and the North East Pharmaceutical Group have a collaboration called Shenyang Eisai Pharmaceutical Co., Ltd. which produces pharmaceutical products. Once the Suzhou facility is fully operational, transfer of production will be done and the Shenyang operation discontinued. The pharmaceutical market in China is expected to expand and the Shenyang and subsequently the Suzhou operations will provide a stable supply to meet market needs.

Name: Eisai Suzhou Pharmaceutical Co., Ltd.
Establishment: March 28, 1996
Location: People's Republic of China, Jiangsu
Province, Suzhou, China-Singapore Industrial Park
Capital: US$16 million
Equity Ownership: East Asia Regional Services Pte. Ltd.
Established: September 1979
Location: Singapore
Equity Ownership: 100% Eisai Co., Ltd. subsidiary
Operations: Sales & management support for subsidiaries in the Asian area
Construction Cost: Approximately US$ 15 million
Total Land Area: Approximately 25,000 square meters
Total Facility Area: Approximately 5,000 square meters
Buildings: Pharmaceutical production facility
(administrative offices, warehouse, maintenance facilities)
Completion Date: 1998 Planned
Operation Date: 2000 Planned
Employees: Approximately 60 when in full operation

Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care systems. The Company reported sales of yen281,561 million in 1996 with approximately 14 percent of sales spent for research and development.